QLT Inc - Premium Company Profile
QLT Inc - Premium Company Profile - New Research Report on Companies and Markets
© companiesandmarkets.com
14.11.2008 22:17:01 www.companiesandmarkets.com adds new report - QLT Inc - Premium Company Profile
(live-PR.com) - www.companiesandmarkets.com/Summary-Company-Prof ..
Introduction
QLT was originally focused on discovering, developing and commercializing innovative therapies in the fields of ophthalmology and dermatology. In 2006, the company changed its focus to purely research and development by selling its manufacturing facility to Tolmar Pharmaceuticals.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information
on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
QLT has two marketed products: Visudyne for the treatment of wet age-related macular degeneration (AMD), pathologic myopia and presumed ocular histoplasmosis and Eligard for the palliative treatment of advanced prostate cancer.
QLT derives its revenues form of product sales (net product revenue and royalties), contract research and development, and licensing and milestones. The company enters into commercial license agreements with pharmaceutical and biotechnology companies to market its products.
The company´s total revenues increased at a CAGR of 11.9% during 2002-2006, from $110.5 million to $175.1 million. This represents an absolute total growth of +$64.6 million for total revenues. The company´s biggest contributor to revenue growth during 2002-2006 was product sales of Visudyne and Eligard.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
Introduction
QLT was originally focused on discovering, developing and commercializing innovative therapies in the fields of ophthalmology and dermatology. In 2006, the company changed its focus to purely research and development by selling its manufacturing facility to Tolmar Pharmaceuticals.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information
|
|
Highlights
QLT has two marketed products: Visudyne for the treatment of wet age-related macular degeneration (AMD), pathologic myopia and presumed ocular histoplasmosis and Eligard for the palliative treatment of advanced prostate cancer.
QLT derives its revenues form of product sales (net product revenue and royalties), contract research and development, and licensing and milestones. The company enters into commercial license agreements with pharmaceutical and biotechnology companies to market its products.
The company´s total revenues increased at a CAGR of 11.9% during 2002-2006, from $110.5 million to $175.1 million. This represents an absolute total growth of +$64.6 million for total revenues. The company´s biggest contributor to revenue growth during 2002-2006 was product sales of Visudyne and Eligard.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
| Author: |
